SCHEMBL1428384

SCHEMBL1428384

CN(CCNC(=O)c1nc(Cl)c(N)nc1N)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCNN1A P37088 8/20 0.39
KCNH2 Q12809 2/20 0.37
GRM5 P41594 1/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
GLA P06280 3/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
NPC1 O15118 2/20 0.35
CYP1A2 P05177 2/20 0.35
GAA P10253 2/20 0.35
CYP2D6 P10635 2/20 0.35
FTO Q9C0B1 2/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
THPO P40225 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CTSA P10619 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428063 0.81 MAPK1 (0.47) SCNN1AGRM5ALDH1A1KDM4EGLA
SCHEMBL1428360 0.81 KCNH2 (0.39) SCNN1AKCNH2GAATDP1NPSR1
SCHEMBL1134533 0.79 TDP1 (0.49) SCNN1AKCNH2GAAMAPTTDP1
SCHEMBL7293251 0.77 SCNN1A (0.42) SCNN1AKCNH2GRM5ALDH1A1KDM4E
SCHEMBL10461270 0.76 SCNN1A (0.43) SCNN1AKCNH2GRM5ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL10334226 0.76 SCNN1A (0.41) SCNN1AKCNH2GRM5ALDH1A1KDM4E
SCHEMBL10462647 0.75 MEN1 (0.44) SCNN1AKCNH2GRM5ALDH1A1KDM4E
SCHEMBL18336734 0.74 FPR3 (0.35) NPC1MAPTRAB9ASMN1; SMN2BTK
SCHEMBL16541800 0.74 SCNN1A (0.53) SCNN1AKCNH2GRM5ALDH1A1KDM4E
SCHEMBL2287885 0.74 SCNN1A (0.41) SCNN1AKCNH2GRM5ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300010-B1 PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2015-03-04 EP disclosed
US-8236808-B2 Pyrazine derivatives as ENAC blockers NOVARTIS AG (CH) 2012-08-07 US disclosed
US-20110201625-A1 Organic Comopunds NOVARTIS AG (CH) 2011-08-18 US disclosed
EP-2300010-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2011-03-30 EP disclosed
WO-2009150137-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201625-A1 Organic Comopunds OR10J3, CFTR, CLIC1 SCNN1A 52/4885KCNH2 49/4885GRM5 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.